“Considerable development across all our modifier gene therapy programs, notable licensing and financing agreements to strengthen our financial position, and meaningful appointments to our leadership team made 2025 a transformative year for Ocugen (OCGN),” said Dr. Shankar Musunuri, Chairman, CEO, Co-founder of Ocugen. “We are poised to leverage upcoming catalysts and advance the business as we near the first of our three BLA filings.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCGN:
- Options Volatility and Implied Earnings Moves Today, March 04, 2026
- Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete
- Options Volatility and Implied Earnings Moves This Week, March 02 – March 05, 2026
- Ocugen Inc (OCGN) Q4 Earnings Cheat Sheet
- Ocugen Appoints Rita Johnson-Greene as New Chief Financial Officer